USANA Health Sciences (NYSE:USNA) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded USANA Health Sciences (NYSE:USNA) from a "hold" to a "buy" rating, despite the MarketBeat consensus remaining "Reduce" with an average target price of $36.00. The company recently reported an earnings beat with EPS of $0.60 against an expected $0.41 and revenue of $226.2 million. However, USANA maintains a modest net margin of 1.16%, a P/E ratio of approximately 39.4, and institutional ownership stands at about 54.25%.
USANA Health Sciences, Inc. (NYSE:USNA) Q4 2025 Earnings Call Transcript
USANA Health Sciences (NYSE:USNA) held its Q4 and fiscal year 2025 earnings call, with CEO Kevin Guest returning to lead the company's next phase of growth. The company is focusing on strategic pillars like scientific excellence, operational discipline, and an aligned global sales force, aiming for a 4% net sales growth at midpoint for fiscal 2026. Key initiatives include expanding omnichannel reach, advancing product innovation, accelerating technology modernization, and driving growth in its venture companies, Rise Wellness and Hiya.
USANA Reports Fiscal Q4 and Full Year 2025 Financial Results
USANA Health Sciences, Inc. announced its financial results for fiscal Q4 and the full year 2025, reporting net sales of $925 million, an 8% year-over-year improvement. The company saw stabilization in active customer counts in its core nutritional business and strong growth in its omnichannel brands, Hiya and Rise, as part of a diversification strategy. USANA projects consolidated net sales between $925 million and $1 billion for fiscal year 2026.
USANA (USNA) Q4 2025 Earnings Call Transcript
USANA Health Sciences (USNA) held its Q4 2025 earnings call, discussing a strategic shift towards a science-driven, omnichannel nutrition company with a projected 4% net sales growth for fiscal year 2026. This growth is primarily expected to come from its Rise Wellness and HYA brands, which are expanding their retail presence in major stores like Costco and Target, and internationally. The company also announced a 10% headcount reduction to achieve $10 million in annualized SG&A savings and highlighted ongoing challenges with a high effective tax rate due to geographic misalignment of revenues and costs.
USNA Q4 Deep Dive: Omnichannel Push and Brand Expansion Shape Outlook Amid Margin Pressures
USANA Health Sciences (USNA) met Q4 CY2025 revenue expectations and significantly beat non-GAAP profit estimates, yet the market reacted negatively due to ongoing margin pressures and a shift towards lower-margin brands. The company is focusing on an omnichannel strategy, new product initiatives, and technology investments, including AI, to drive future growth despite acknowledging continued gross margin headwinds. Key areas of focus for upcoming quarters include the expansion pace of new brands (Hiya, Rise Wellness) and the effectiveness of technology upgrades and cost discipline in stabilizing margins.
USANA Health Sciences (NYSE:USNA) Upgraded by Zacks Research to Hold Rating
Zacks Research upgraded USANA Health Sciences (NYSE:USNA) from a "strong sell" to a "hold" rating, though other analysts like Weiss Ratings maintain a "sell" rating. The company recently reported better-than-expected earnings, with $0.60 EPS against an anticipated $0.41, and revenue of $226.2 million. Despite mixed analyst views, institutional ownership remains significant, and several funds have increased their positions in the stock.
Usana reports Q4 EPS 60c vs. 64c last year
Usana (USNA) reported Q4 EPS of 60 cents, down from 64 cents last year, despite achieving Q4 revenue of $226.2 million, an increase from $213.6 million in the prior year. The company's Chairman and CEO, Kevin Guest, noted stabilization in active customer counts in the core nutritional business, with modest sequential growth led by markets like mainland China, the United States, and Canada, while omnichannel brands Hiya and Rise also showed solid year-over-year growth.
USANA Health Sciences (NYSE:USNA) Releases Earnings Results, Beats Estimates By $0.19 EPS
USANA Health Sciences (NYSE:USNA) reported quarterly earnings of $0.60 per share, surpassing analyst estimates of $0.41 by $0.19. Despite beating estimates, the company's shares fell to $20.61 on Tuesday, with a market capitalization of $376.75 million. Analysts maintain a consensus "Reduce" rating for the stock, with an average price target of $36.00.
USANA Health: Fourth Quarter Earnings Overview
USANA Health Sciences reported a net loss of $1.8 million, or $0.10 per share, for the fourth quarter, with adjusted earnings of $0.60 per share and revenue of $226.2 million. For the full year, the company achieved a net income of $10.8 million ($0.58 per share) on $925.3 million in revenue. Looking ahead, USANA projects full-year earnings per share between $1.95 and $2.29 and revenue between $925 million and $1 billion.
USANA Health Sciences earnings beat by $0.20, revenue topped estimates
USANA Health Sciences (NYSE: USNA) reported strong fourth-quarter results, beating analyst expectations for both EPS and revenue. The company posted an EPS of $0.60 on revenue of $226.2 million, surpassing the consensus estimates. USANA also provided optimistic guidance for FY 2026, foreseeing EPS between $1.95-$2.29 and revenue of $920 million-$1 billion.
USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook
USANA Health Sciences announced its financial results for the fourth quarter and full fiscal year 2025, along with its outlook for fiscal year 2026. The company reported a net loss in Q4 2025 but saw an 8% increase in fiscal year 2025 net sales, primarily driven by its Hiya brand, and provided guidance for continued growth in 2026 with an emphasis on its omnichannel strategy and new product lines like Rise Wellness. The company also detailed non-GAAP financial measures and reconciliations, emphasizing its strong balance sheet and strategic investments for future growth.
USANA Health: Q4 Earnings Snapshot
USANA Health Sciences Inc. reported a loss of $1.8 million in its fourth quarter, translating to a loss of 10 cents per share, though adjusted earnings were 60 cents per share. The nutritional supplement maker posted revenue of $226.2 million for the quarter and $925.3 million for the full year, with an annual profit of $10.8 million. The company forecasts full-year earnings between $1.95 and $2.29 per share and revenue between $925 million and $1 billion.
USANA Health Sciences (USNA) Q4 Earnings and Revenues Beat Estimates
USANA Health Sciences (USNA) reported Q4 earnings of $0.6 per share, significantly surpassing the Zacks Consensus Estimate of $0.41, despite being lower than the $0.64 reported a year ago. The company also beat revenue estimates, posting $226.2 million against an anticipated $213.61 million. USANA Health's stock has seen a 6.5% increase year-to-date, outperforming the S&P 500's slight decline.
Q3 EPS Estimate for USANA Health Sciences Cut by Analyst
Sidoti Csr analyst A. Lebiedzinski has reduced the Q3 2026 EPS estimate for USANA Health Sciences (NYSE:USNA) to $0.49 from $0.54 and lowered the FY2026 outlook to $1.84 per share, significantly below the consensus of $2.45. This downgrade reflects negative analyst sentiment, with Zacks issuing a "strong sell" rating and Weiss Ratings reiterating a "sell (d)". The company's stock currently trades around $20.95, near its 12-month low, and institutional investors hold a 54.25% stake.
USANA (USNA) To Report Earnings Tomorrow: Here Is What To Expect
USANA Health Sciences (USNA) is set to announce its earnings results, with analysts expecting a 5.8% year-on-year revenue growth to $226 million and adjusted earnings of $0.41 per share. The company met revenue expectations last quarter but missed gross margin estimates, although it had an impressive beat on EBITDA. Investors are keenly watching as USANA's stock performance has lagged its peers in the personal care segment over the last month.
Analysts Estimate USANA Health Sciences (USNA) to Report a Decline in Earnings: What to Look Out for
USANA Health Sciences (USNA) is expected to report a year-over-year decline in earnings but higher revenues for the quarter ended December 2025. Analysts predict earnings of $0.41 per share, a 35.9% decrease, on revenues of $225.96 million, a 5.8% increase. The company's Zacks Earnings ESP is 0% and it carries a Zacks Rank of #4, making an earnings beat difficult to predict conclusively.
Analysts Estimate USANA Health Sciences (USNA) to Report a Decline in Earnings: What to Look Out for
Analysts are forecasting a year-over-year decline in USANA Health Sciences' (USNA) earnings for the quarter ended December 2025, despite an expected increase in revenues. The company's Earnings ESP (Expected Surprise Prediction) is 0%, and it holds a Zacks Rank of #4, making it difficult to predict an earnings beat. Investors are advised to consider other factors beyond just earnings estimates when evaluating USANA stock.
USANA Health Sciences (USNA) to Release Quarterly Earnings on Tuesday
USANA Health Sciences (USNA) is set to release its Q4 2025 earnings after market close on Tuesday, February 17th, with analysts forecasting $0.41 EPS and revenues of approximately $225.96 million. The company's stock, currently trading at $21.12, has a market cap of $385.98 million and has seen mixed analyst ratings, with a consensus of "Reduce" and a target price of $36.00. Institutional investors hold a significant portion of shares, with Vanguard Group Inc. being a notable holder.
3 Reasons to Avoid USNA and 1 Stock to Buy Instead
USANA Health Sciences (USNA) stock has dropped significantly, leading analysts to advise caution. The company is not recommended due to declining revenue, limited distribution channels as a small consumer staples company, and a negative trend in earnings per share. Instead, the article suggests focusing on other high-quality stocks that have shown strong momentum and market-beating returns.
USANA Exec. Chairman/CEO Kevin Guest on Self-Renewal Day: Break Comfort Zones for Strategic Growth with Six Steps
Kevin Guest, Executive Chairman & CEO of USANA Health Sciences, encourages leaders to embrace Self-Renewal Day by breaking comfort zones for strategic growth. He outlines six steps, including conducting a personal audit, reconnecting with core values, and committing to positive self-talk, to help executives transform their careers and lives. Guest emphasizes that true renewal involves conscious choices and courage to realign for purpose, drawing lessons from his own experiences and his book, "All the Right Reasons."
He left a rock musician dream to lead a global company: 6 steps
USANA Executive Chairman and CEO Kevin Guest observed Self-Renewal Day by encouraging leaders to move beyond their comfort zones for strategic growth. He outlined six steps for personal and professional renewal, including conducting a personal audit, reconnecting with core values, and making courageous decisions. Guest, who once left a music career for leadership, highlighted how proceeds from his book "All the Right Reasons" benefit the USANA Foundation, providing over 112 million meals to date.
USANA Exec. Chairman/CEO Kevin Guest on Self-Renewal Day: Break Comfort Zones for Strategic Growth with Six Steps
USANA Executive Chairman & CEO Kevin Guest marks Self-Renewal Day by urging business leaders to break comfort zones for strategic growth. He shares six steps for personal and professional renewal, emphasizing the importance of aligning with core values and embracing change. Guest highlights his own journey from aspiring musician to CEO and promotes his book, "All the Right Reasons," which benefits the USANA Foundation.
USANA Exec. Chairman/CEO Kevin Guest on Self-Renewal Day: Break Comfort Zones for Strategic Growth with Six Steps
On Self-Renewal Day, USANA Health Sciences Executive Chairman & CEO Kevin Guest urges business leaders to break free from comfort zones and pursue strategic growth. Guest, author of "All the Right Reasons," emphasizes that true renewal involves making courageous decisions, realigning with core values, and embracing discomfort for long-term fulfillment. He outlines six steps, including conducting a personal audit, making courageous decisions, and reframing resilience, to help leaders elevate their performance and drive purposeful growth.
Equities Analysts Set Expectations for USNA Q3 Earnings
Sidoti Csr has increased its Q3 2026 EPS estimate for USANA Health Sciences (NYSE:USNA) to $0.54 and projects FY2026 EPS at $1.95, while the consensus full-year estimate stands at $2.45. The company recently missed Q3 expectations, reporting -$0.15 EPS against an estimated $0.47, and provided FY2025 guidance of $1.73 EPS. Market sentiment remains negative with an average "Reduce" rating from analysts and recent insider selling activity.
USANA Health Sciences' (NYSE:USNA) earnings have declined over five years, contributing to shareholders 75% loss
USANA Health Sciences (NYSE:USNA) has seen its share price fall by 75% over the past five years, with earnings per share declining by 30% annually during the same period. Although the stock recently rose 10% in a week, this does not offset the substantial long-term losses. The company's performance has also lagged the broader market, which gained 17% in the last year, suggesting unresolved challenges.
Sidoti Csr Has Bullish Outlook for USNA FY2025 Earnings
Sidoti Csr increased its FY2025 EPS estimate for USANA Health Sciences to $1.74, despite the company recently missing Q3 results and setting its own FY2025 guidance at $1.73 EPS. Analyst sentiment remains negative with an average "Reduce" rating and a $36 price target, while USANA's stock currently trades around $21.60. Insider selling has been noted, although institutions hold approximately 54% of the shares.
USANA leans on kids vitamins and snack bars for 2026 sales push
USANA Health Sciences announced preliminary net sales of $925 million for fiscal year 2025, exceeding its guidance of $920 million. The company issued initial net sales guidance for fiscal year 2026 ranging from $925 million to $1.0 billion, driven by expected strong performance from its Hiya (children's health) and Rise Wellness (snack bars) segments. USANA will provide further details and updated financial results at the 28th Annual ICR Conference and during its Q4 and full fiscal year 2025 earnings release.
USANA forecasts 2026 sales up to $1 billion, expects growth in subsidiaries
USANA Health Sciences, Inc. anticipates fiscal year 2025 net sales of approximately $925 million, slightly above previous guidance. The company projects 2026 revenue between $925 million and $1 billion, driven by significant growth in its subsidiaries Hiya and Rise Wellness, despite expected declines in its core nutritional business. USANA plans strategic investments in these growing segments and maintains strong financial health with impressive gross profit margins and liquidity.
USANA Health Sciences Projects $925M in 2025 Net Sales, Exceeding Guidance
USANA Health Sciences (USNA) has projected consolidated net sales of $925 million for fiscal year 2025, surpassing its previous guidance and analyst consensus, driven by strong performance in its nutritional business. The company also provided an initial 2026 sales outlook ranging from $925 million to $1 billion, indicating continued growth, especially from its Hiya and Rise Wellness segments. This positive outlook led to a 1.4% pre-market stock increase.
USANA forecasts 2026 sales up to $1 billion, expects growth in subsidiaries
USANA Health Sciences, Inc. forecasts fiscal year 2026 net sales between $925 million and $1 billion, despite an expected decline in its core nutritional business. This growth is anticipated to come from its subsidiaries, Hiya and Rise Wellness, which are projected to see significant sales increases. The company plans to invest heavily in these subsidiaries while maintaining strong gross profit margins and a healthy balance sheet.
USANA Health Issues Updated 2025-2026 Sales Outlook
USANA Health Sciences (USNA) provided an updated 2025 sales forecast of approximately $925 million, slightly above previous guidance. The company also issued an initial 2026 sales outlook ranging from $925 million to $1.0 billion, anticipating softer core nutritional business sales offset by growth from Hiya and Rise Wellness. Spark, TipRanks’ AI Analyst, rates USNA as Neutral due to compressed profitability and weaker cash generation, despite strong revenue growth.
Zacks Research Downgrades USANA Health Sciences (NYSE:USNA) to Strong Sell
Zacks Research has downgraded USANA Health Sciences (NYSE:USNA) from a "hold" to a "strong sell" rating, with the stock's consensus rating now "Reduce" and an average target price of $36.00. The downgrade follows USANA setting its FY2025 EPS guidance noticeably below analysts' expectations, signaling a weaker outlook, coupled with recent insider stock sales and the stock's 50-day moving average falling below its 200-day moving average.
Kevin Guest Returns to USANA Health Sciences as CEO
USANA Health Sciences, Inc. announced that Kevin Guest is returning as Chief Executive Officer, effective immediately. Guest, who previously served as CEO for eight years and most recently as Executive Chairman, replaces Jim Brown. The company's board believes this leadership change will accelerate strategic priorities and long-term growth.
Kevin Guest returns to lead health and wellness company USANA again
USANA Health Sciences (NYSE: USNA) has announced the return of Kevin Guest as CEO, effective immediately. Mr. Guest, who previously served as CEO for eight years and most recently as Executive Chairman, is re-assuming the leadership role to accelerate growth and enhance shareholder value. This transition sees Jim Brown stepping down from his position as CEO and President, with the Board expressing confidence that Guest's experience will drive the company's strategic priorities.
USANA Health Sciences (NYSE: USNA) shifts leadership as Kevin Guest returns as CEO
USANA Health Sciences (NYSE: USNA) announced a leadership transition where Jim Brown stepped down as CEO and President, effective January 8, 2026, and will serve in an advisory role. Kevin Guest, the current Executive Chairman and former CEO, will reassume the CEO position while continuing as Chairman. The Compensation Committee is still determining the compensation arrangements for both Mr. Brown's separation and Mr. Guest's new role, with details to be disclosed later.
About Us | Oil & Gas Journal - Kevin Guest Returns to USANA Health Sciences as CEO
USANA Health Sciences, Inc. announced that Kevin Guest is returning to lead the company as Chief Executive Officer, effective immediately. Mr. Guest previously served as CEO for eight years and most recently as Executive Chairman, bringing over three decades of experience with USANA. This leadership transition aims to accelerate growth and enhance shareholder value, with Mr. Guest succeeding Jim Brown, who has stepped down as CEO and President.
Eight Years at the Top: USANA Malaysia Named #1 Combination Dietary Supplements Brand by Euromonitor International
USANA Malaysia has been recognized for the eighth consecutive year as the top Combination Dietary Supplements brand in Malaysia by Euromonitor International. This achievement reflects USANA's sustained commitment to quality, science, and excellence in the nutrition industry. The company expresses gratitude to its customers and notes its continued mission to empower individuals with high-quality, science-backed nutritional products.
USANA Executive Chairman Kevin Guest Shares Timeless Lessons for a 2026 Growth Mindset
Kevin Guest, Executive Chairman of USANA Health Sciences, encourages professionals to adopt a growth mindset for 2026, emphasizing resilience, curiosity, purpose, and awareness. Drawing from his book, "All the Right Reasons," he highlights how embracing these qualities and learning from setbacks can lead to lasting achievement. Guest also suggests strategies like finding mentors, practicing positive self-talk, serving others, and trusting intuition as pathways to personal and professional growth.
USANA Executive Chairman Kevin Guest Shares Timeless Lessons for a 2026 Growth Mindset
USANA Executive Chairman Kevin Guest emphasizes the importance of a growth mindset for lasting achievement and fulfillment as leaders look to the new year. He identifies four key traits—resilience, curiosity, purpose, and awareness—as crucial for building such a mindset, drawing from his book "All the Right Reasons." Guest also provides strategies for personal and professional growth, including finding mentors, practicing positive self-talk, serving others, and trusting intuition.
USANA Executive Chairman Kevin Guest Shares Timeless Lessons for a 2026 Growth Mindset
Kevin Guest, Executive Chairman at USANA Health Sciences, encourages professionals to adopt a growth mindset for long-term achievement, emphasizing resilience, curiosity, purpose, and awareness. He shares four strategies, including finding mentors and practicing positive self-talk, and highlights the impact of his book "All the Right Reasons," whose proceeds benefit the USANA Foundation.
Personal Care Stocks Q3 Results: Benchmarking USANA (NYSE:USNA)
This article benchmarks USANA (NYSE:USNA) against its peers in the personal care sector, analyzing their Q3 earnings results. While USANA's revenue was in line with expectations, Nature's Sunshine (NATR) significantly outperformed, making it the strongest performer of the quarter. Edgewell Personal Care (EPC) showed a weaker performance, with similar struggles reported by Medifast (MED) and Coty (COTY).
Personal Care Stocks Q3 Results: Benchmarking USANA (NYSE:USNA)
This article analyzes the Q3 2025 financial results for USANA Health Sciences (NYSE:USNA) and its peers in the personal care sector. It highlights USANA's satisfactory quarter with in-line revenues and an EBITDA beat, contrasting it with Nature's Sunshine's strong performance and Edgewell's softer quarter. The report also briefly touches on Medifast and Coty's results, providing a benchmark of the industry's performance.
This Utah program quietly turned school break into 205,720 free meals
The USANA Foundation's annual holiday food pack initiative delivered 205,720 meals to 65 schools across Utah, ensuring children had access to nutritious food during winter break. This effort involved 632 volunteers and complemented the year-round USANA Kids Eat program, which in 2025 provided 327,166 meals to 49 schools. The initiative highlights the ongoing fight against childhood food insecurity in Utah.
USANA Foundation Shares Holiday Cheer with Meals for Utah Students and Families
The USANA Foundation, through its Utah-focused Kids Eat program, mobilized its annual holiday food pack initiative, delivering over 5,100 food bags equivalent to 205,720 meals to 65 schools across Utah. This program, supported by 632 volunteers, aims to combat food insecurity during school breaks, especially critical with one in nine children at risk of hunger in Utah. The initiative highlights USANA's commitment to fighting hunger both locally and globally.
Trust Your Gut--USANA's Probiotic Earns ConsumerLab.com Seal of Approval
USANA's Probiotic supplement has received the ConsumerLab.com Seal of Approval, recognizing its high standards for purity, potency, and scientific accuracy. This certification validates USANA's commitment to providing premium, trustworthy products that support gut health. The probiotic contains researched strains like Lactobacillus rhamnosus GG and Bifidobacterium BB-12, formulated for survivability and stability.
Trust Your Gut--USANA's Probiotic Earns ConsumerLab.com Seal of Approval
USANA's Probiotic supplement has received the distinguished ConsumerLab.com Seal of Approval, indicating it meets high standards for purity, potency, and scientific accuracy. This certification validates USANA's commitment to quality in providing a product designed to support healthy digestion, nutrient absorption, and overall well-being. The probiotic contains well-researched strains like Lactobacillus rhamnosus GG and Bifidobacterium BB-12, supported by technology ensuring bacterial viability.
USANA (NYSE: USNA) probiotic passes ConsumerLab.com purity, potency tests
USANA's Probiotic supplement has received the ConsumerLab.com Seal of Approval after comprehensive third-party testing confirmed its purity, potency, viability, and label accuracy. The product, containing Lactobacillus rhamnosus GG (LGG) and Bifidobacterium BB-12, is designed to support gut health and maintain stated bacterial levels through expiration. This certification reinforces USANA's commitment to quality amidst a backdrop of mixed stock reactions to recent positive announcements.
USANA Health Sciences (NYSE:USNA) Insider David Mulham Mulham Sells 873 Shares of Stock
USANA Health Sciences (NYSE:USNA) insider David Mulham Mulham sold 873 shares of the company's stock on December 10th at an average price of $21.00, totaling $18,333.00. This sale decreased his stake by 9.43% to 8,387 shares. The transaction, disclosed in an SEC filing, occurred as USNA traded down 1.9% to $20.47 on light volume, with analysts generally rating the stock as "Hold/Reduce."
Insider Sell: David Mulham Sells 873 Shares of Usana Health Scie
David Mulham, Chief Sales Officer of Usana Health Sciences Inc (USNA), sold 873 shares of the company on December 10, 2025, reducing his holdings to 8,387 shares. Over the past year, there have been 18 insider sells and no insider buys at USNA. The stock is currently trading at $21, significantly undervalued based on its GF Value of $48.24.
USANA Health Sciences (NYSE:USNA) Upgraded at Zacks Research
Zacks Research has upgraded USANA Health Sciences (NYSE:USNA) from a "strong sell" to a "hold" rating, contributing to an average "Reduce" rating with a $36.00 target price from analysts. The company's stock opened at $20.90, and it recently reported Q3 EPS of $0.56 on $200.2 million revenue, with future Q3 2025 EPS guidance set at -0.15. Insider transactions show recent share sales, while institutional investors hold over 54% of the company's stock.
